Regorafenib is an orally active multi-kinase inhibitor with antitumor and antiangiogenic effects, targeting VEGFRs, RET, PDGFRβ, and c-Kit in cancer research. Reagent-grade; for laboratory research purposes only.
Usually ships within 24 hours.